Get notified of page updates
Federal Public Policy Initiatives
Review some of FORCE's current legislative and regulatory policy priorities that impact the hereditary cancer community.

Stay up to date on research and information

Sign Up for FORCE Newsletters

Policy Archive

FDA Approves New Direct-to-Consumer Genetic Test for 3 BRCA Mutations

Genetic Counseling & Testing

On March 6, 2018, the Food and Drug Administration (FDA) announced approval of a new direct-to-consumer genetic test for three BRCA mutations most commonly found in people with Ashkenazi Jewish (Eastern European) ancestry, often referred to as founder mutations.

With thousands of known BRCA mutations, 23andMe's "Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants)" provides consumers with an extremely limited snapshot of potential hereditary cancer risk. 

Read our official statement

Take Action Now Become an Advocate 2024 Priorities Federal Policy State Policy Advocacy Archive

News Briefs

9/25/2024 - Sent a letter to members of the Senate Judiciary Committee strongly opposing efforts to advance S. 2140, the Patent Eligibility Restoration Act (PERA), which would allow patents on abstract ideas, laws of nature, and natural phenomena.

9/9/2024 - Signed on to a comment letter encouraging coverage of computed tomography colonography (CTC) procedures and follow-up colonoscopies in the proposed Medicare and Medicaid Program 2025 Physician Fee Schedule (PFS) rule.

8/2/2024 - Responded to an RFI from Representatives DeGette and Bucshon, providing input on the successes, gaps and unmet needs in the 21st Century Cures and CURES 2.0 initiatives, suggesting components for future efforts.

More